Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025999 | 0.99 | CHRNA7 (0.61) | CHRNA7LMNAMAPK1TP53MAPT | |
| SCHEMBL3032801 | 0.89 | CHRNA7 (0.72) | CHRNA7LMNAMAPK1MAPTCYP2D6 | |
| SCHEMBL3030712 | 0.87 | CHRNA7 (0.68) | CHRNA7LMNAMAPK1TP53MAPT | |
| SCHEMBL3025992 | 0.87 | CHRNA7 (0.68) | CHRNA7LMNAMAPK1TP53MAPT | |
| SCHEMBL3029276 | 0.86 | CHRNA7 (0.80) | CHRNA7MAPK1CYP2D6 | |
| SCHEMBL3036106 | 0.86 | CHRNA7 (0.67) | CHRNA7LMNAMAPK1TP53MAPT | |
| SCHEMBL2888752 | 0.80 | CHRNA7 (0.72) | CHRNA7LMNAMAPK1TP53MAPT | |
| SCHEMBL7169230 | 0.80 | LMNA (0.63) | CHRNA7LMNATP53MAPTALDH1A1 | |
| SCHEMBL16403251 | 0.79 | CHRNA7 (0.81) | CHRNA7LMNAMAPK1TP53MAPT | |
| SCHEMBL3013759 | 0.78 | LMNA (0.63) | CHRNA7LMNATP53MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609713-B2 | Pyrrole derivatives and their methods of use | ABBVIE INC. (US) | 2013-12-17 | — | — | US | claimed |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | claimed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | claimed |
| US-8609713-B2 | Pyrrole derivatives and their methods of use | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-7741364-B2 | Neuronal nicotinic acetylcholine receptor modulators; such as ethyl 1-[4-(aminosulfonyl)phenyl]-5-(4-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate | ABBOTT LABORATORIES (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | PYCR1, PPOX, DHPS | CHRNA7 4801/4885LMNA 3511/4885MAPK1 4366/4885 |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | PYCR1, PPOX, DHPS | CHRNA7 4801/4885LMNA 3511/4885MAPK1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.